IR@PKUHSC  > 北京大学临床肿瘤学院  > 肿瘤内科
学科主题临床医学
Glioblastoma multiforme: a review of where we have been and where we are going
Adamson, Cory1,2; Kanu, Okezie O.3; Mehta, Ankit I.1; Di, Chunhui1; Lin, Ningjing4; Mattox, Austin K.1; Bigner, Darell D.1
关键词Gbm Genetics Glioblastoma Multiforme Oncogenomics Signaling Cascades
刊名EXPERT OPINION ON INVESTIGATIONAL DRUGS
2009-08-01
DOI10.1517/13543780903052764
18期:8页:1061-1083
收录类别SCI
文章类型Review
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]PRIMARY INTRACRANIAL TUMORS ; HIGH-GRADE ASTROCYTOMA ; GROWTH-FACTOR RECEPTOR ; COMPARATIVE GENOMIC HYBRIDIZATION ; PLACEBO-CONTROLLED TRIAL ; THERAPY-ONCOLOGY-GROUP ; PRIMARY BRAIN-TUMORS ; PHASE-III TRIAL ; RECURSIVE PARTITIONING ANALYSIS ; BEVACIZUMAB PLUS IRINOTECAN
英文摘要

Malignant gliomas such as glioblastoma multiforme (GBM) present some of the greatest challenges in the management of cancer patients worldwide, despite notable recent achievements in oncology. Even with aggressive surgical resections using state-of-the-art preoperative and intraoperative neuroimaging, along with recent advances in radiotherapy and chemotherapy, the prognosis for GEM patients remains dismal: median survival after diagnosis is about 14 months. Established good prognostic factors are limited, but include young age, high Karnofsky Performance Status (KPS), high mini-mental status examination score, O6-methylguanine methyltransferase promoter methylation, and resection of > 98% of the tumor. Standard treatment includes resection, followed by concurrent chemotherapy and radiotherapy. GBM research is being conducted worldwide at a remarkable pace, with some of the more recent promising studies focused on identification of aberrant genetic events and signaling pathways, tumor stem cell identification and characterization, modulation of tumor immunological responses, combination therapies, and understanding of the rare long-term survivors. Past treatment strategies have failed for various reasons; however, newer strategies in trials today and on the horizon encourage optimism. To help illustrate ′where we have been′ with this fatal disease and ′where we are going′ with contemporary studies, we include in this review a detailed history of Phase III clinical trials for GBM, with a final emphasis on exciting new treatment strategies that offer hope for future GBM therapy.

语种英语
WOS记录号WOS:000268789900002
引用统计
被引频次:246[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56289
专题北京大学临床肿瘤学院_肿瘤内科
北京大学临床肿瘤学院_淋巴肿瘤内科
作者单位1.Duke Med Ctr, Durham, NC 27712 USA
2.Durham VA Med Ctr, Neurosurg Sect, Durham, NC USA
3.Univ Lagos, Teaching Hosp, Lagos, Nigeria
4.Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Oncol, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Adamson, Cory,Kanu, Okezie O.,Mehta, Ankit I.,et al. Glioblastoma multiforme: a review of where we have been and where we are going[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS,2009,18(8):1061-1083.
APA Adamson, Cory.,Kanu, Okezie O..,Mehta, Ankit I..,Di, Chunhui.,Lin, Ningjing.,...&Bigner, Darell D..(2009).Glioblastoma multiforme: a review of where we have been and where we are going.EXPERT OPINION ON INVESTIGATIONAL DRUGS,18(8),1061-1083.
MLA Adamson, Cory,et al."Glioblastoma multiforme: a review of where we have been and where we are going".EXPERT OPINION ON INVESTIGATIONAL DRUGS 18.8(2009):1061-1083.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Adamson, Cory]的文章
[Kanu, Okezie O.]的文章
[Mehta, Ankit I.]的文章
百度学术
百度学术中相似的文章
[Adamson, Cory]的文章
[Kanu, Okezie O.]的文章
[Mehta, Ankit I.]的文章
必应学术
必应学术中相似的文章
[Adamson, Cory]的文章
[Kanu, Okezie O.]的文章
[Mehta, Ankit I.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。